The role of APOBEC in early-stage epidermal growth factor receptor-mutant non-small cell lung cancer [0.03%]
APOBEC在表皮生长因子受体突变的早期非小细胞肺癌中的作用
Hyun Ae Jung,Jinyeong Lim,Yoon-La Choi et al.
Hyun Ae Jung et al.
Background: APOBEC plays a crucial role in the mutation process and immune response of non-small cell lung cancer (NSCLC). This study evaluated the role of the APOBEC mutation signature in early-stage epidermal growth fac...
Effect of treatment sequencing on outcome of patients with non-small cell lung cancer with a synchronous solitary extrathoracic metastasis [0.03%]
不同治疗模式对同步发生单发肺外转移非小细胞肺癌患者预后的影响
Mandy Jongbloed,Ronald A M Damhuis,Wouter H Van Geffen et al.
Mandy Jongbloed et al.
Currently, guidelines advise local radical treatment (LRT) to all disease sites in addition to systemic therapy in patients with synchronous oligometastatic non-small cell lung cancer (NSCLC). However, the best order of treatments is unknow...
Inavolisib for PIK3CA-mutant non-small cell lung cancer: A case report [0.03%]
PIK3CA突变非小细胞肺癌应用INAVOLISIB治疗的病例报告
Lei Cheng,Dongying Wang,Xueyan Zhang et al.
Lei Cheng et al.
Introduction: PIK3CA mutations are oncogenic drivers in 2-4% of non-small cell lung cancers (NSCLC), often co-occurring with other drivers and conferring therapeutic resistance. This report is unique in describing the eff...
Tarlatamab in routine clinical care: How much safety is enough? [0.03%]
tarlatamab在常规临床护理中的安全性评估：足够的安全标准是多少？
Ernest Nadal,Jordi Bruna
Ernest Nadal
Cost-effectiveness of adjuvant alectinib in the treatment of patients with resected stage IB-IIIA ALK-positive non-small lung cancer in France, based on the ALINA study [0.03%]
基于ALINA研究的ALK阳性IB至IIIA期非小细胞肺癌术后患者接受阿来替尼辅助治疗的成本效益分析-法国数据
Romain Supiot,Alexandre Gherardi,Léopoldine du Manoir de Juaye et al.
Romain Supiot et al.
Background and objective: Alectinib has demonstrated significant disease-free survival (DFS) benefits as adjuvant therapy for resected stage IB-IIIA ALK-positive non-small-cell lung cancer (NSCLC) in the ALINA study. This...
Optimizing communication for ultrafast lung cancer biomarker testing: the UTOPIA pilot study [0.03%]
一种针对超快速肺癌生物标志物检测的优化沟通方法：UTOPIA 前瞻性研究
Susana Hernandez,Esther Conde,Marta Alonso et al.
Susana Hernandez et al.
Background: Non-small cell lung carcinoma (NSCLC) is a leading example of precision oncology, with a growing number of actionable targets. However, long turnaround times (TAT) for biomarker results can delay optimal treat...
Neighborhood matters: Predicting lung cancer screening adherence with explainable AI [0.03%]
邻里关系重要性：使用可解释的人工智能预测肺癌筛查依从性
Kun-Han Lu,Yi Xiao,Aamna Akhtar et al.
Kun-Han Lu et al.
Background: This study builds a predictive model for lung cancer screening (LCS) adherence using social determinants of health (SDOH) data in high-risk populations. By identifying key factors influencing non-adherence, we...
Multiomic analysis of treatment-naïve NSCLC before the era of neoadjuvant immunotherapy reveals contrasting immune phenotypes in stage IIIA: node-dominant (T1N2) exhibiting hot versus tumor-dominant (T4N0) cold features [0.03%]
免疫治疗新辅助时代之前的未经治疗的非小细胞肺癌的多组学分析揭示了III期两种不同免疫表型：以淋巴结为主的IIIA期（T1N2）具有“热”特征，而以肿瘤为主的IIIA期(T4N0)则具有“冷”特征
Duk Ki Kim,Yooyoung Chong,Min-Kyung Yeo et al.
Duk Ki Kim et al.
Background: Non-small cell lung cancer (NSCLC) exhibits substantial heterogeneity in its tumor immune microenvironment, which critically influences therapeutic outcomes. Recently, immune checkpoint inhibitors (ICIs) have ...
Neoadjuvant immunotherapy plus chemotherapy in locally advanced stage III NSCLC patients undergoing definitive chemo-radiotherapy---a real‑world multicenter retrospective study [0.03%]
局部晚期III期非小细胞肺癌新辅助免疫治疗联合化疗后进行根治性放化疗的真实世界多中心回顾性研究
Guoyin Li,Chaoyuan Liu,Pan Xi et al.
Guoyin Li et al.
Background: The optimal integration of immunotherapy with definitive chemoradiotherapy (CRT) for unresectable stage III non-small cell lung cancer (NSCLC) remains an area of active investigation. While consolidation immun...
Locoregional therapies in advanced and recurrent pleural mesothelioma: A systematic review [0.03%]
晚期和复发性胸膜间皮瘤的局部区域疗法：系统评价
Paolo Ambrosini,Thierry Berghmans,Mario Occhipinti et al.
Paolo Ambrosini et al.
Background: Locoregional therapies, including radiotherapy, surgery and other ablative techniques, are occasionally used as strategies to manage oligorecurrent or oligoprogressive pleural mesothelioma. Yet, their real-wor...